Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo | Zendy

Michael Marks | Zendy; Hilary Toloka | Zendy; Ciara Baker | Zendy; Christian Kositz | Zendy; James Asugeni | Zendy; Elliot Puiahi | Zendy; Rowena Asugeni | Zendy; Kristy Azzopardi | Zendy; Jason Diau | Zendy; John Kaldor | Zendy; Lucia Romani | Zendy; Michelle RedmanMacLaren | Zendy; David MacLaren | Zendy; Anthony W. Solomon | Zendy; David Mabey | Zendy; Andrew C. Steer | Zendy

Open Access

Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo

Author(s) -

Michael Marks,

Hilary Toloka,

Ciara Baker,

Christian Kositz,

James Asugeni,

Elliot Puiahi,

Rowena Asugeni,

Kristy Azzopardi,

Jason Diau,

John Kaldor,

Lucia Romani,

Michelle RedmanMacLaren,

David MacLaren,

Anthony W. Solomon,

David Mabey,

Andrew C. Steer

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy574

Subject(s) - impetigo , ivermectin , azithromycin , medicine , scabies , staphylococcus aureus , skin infection , dermatology , antibiotics , veterinary medicine , microbiology and biotechnology , biology , genetics , bacteria

Scabies is a public health problem in many countries, with impetigo and its complications important consequences. Ivermectin based mass drug administration (MDA) reduces the prevalence of scabies and, to a lesser extent, impetigo. We studied the impact of co-administering azithromycin on the prevalence of impetigo and antimicrobial resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research